Scientists from the University of Bern have reported preclinical data on KiH_E07_79, a designed ankyrin repeat protein (DARPin) consisting of an Fc fusion construct comprising E07, an immunoglobulin E (IgE)-binding protein, and E2_79, an IgE disruptive domain, fused to an IgG Fc domain via a GS-rich linker.
Kling Biotherapeutics BV has presented preclinical data on an antibody, KBA-1413, which recognizes a specific glycoform of CD43 that is shared among acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and solid tumor cells.
Companies and investors, well aware of the natural up and down fluctuations of the market, keep expecting the current downturn to end. They’ve been expecting it to begin an upturn for the past two years. During a Feb. 26 session on venture capital trends at the BIO CEO & Investor Conference in New York, investors said the tough times might well extend further into 2024 than they would like.
The standard therapy for moderate to severe cases of ulcerative colitis (UC) is treatment with infliximab, but it is estimated that about 40% of patients with UC do not respond to it. An international team of investigators set out to study the causes behind this, which are not clearly understood.
Researchers from Sitryx Therapeutics Ltd. and affiliated organizations presented data from a study that aimed to assess the potential of selective salt-inducible kinase 2 (SIK2) inhibition as a therapeutic strategy for the treatment of ulcerative colitis.
Preventing the interaction between the cellular adhesion integrin α4β7 and endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is a validated strategy for Crohn’s disease and ulcerative colitis treatment. Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical efficacy data on SPY-001, a long-acting monoclonal antibody targeting integrin α4β7.
Researchers from Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical data for SPY-002, a novel extended half-life, fully human IgG1 monoclonal antibody (MAb) targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A), being developed for the treatment of inflammatory bowel disease (IBD).
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.
Plexin domain containing 2 (PLXDC2) is expressed on the surface of several cell types, such as macrophages, dendritic or epithelial cells. Its activation reduces oxidative stress and rebalances the immune response and decreases inflammation. Its activation has been seen to improve disease severity in models of rheumatoid arthritis, while its blockade or loss exacerbates the severity of dextran sulfate sodium (DSS)-induced colitis. Researchers hence tested the PLXDC2 agonist PX-04 (Landos Biopharma Inc.) in a DSS-induced murine model of colitis.